Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-13-66 | Oral Session 13: Basic 3 | ETA2022

Generation of human thyroid organoids from embryonic stem cells to rescue hypothyroidism

Romitti Mirian , Tourneur Adrien , Lasolle Helene , Detours Vincent , Singh Sumeet , Refetoff Samuel , Costagliola Sabine

Organoids are tiny, self-organized three-dimensional versions of an organ that are produced in vitro. Human organoids offer unique opportunities to model the development, physiology, and diseases of human tissues while complementing animal models and reducing the need for animal testing. In the thyroid field, there is a lack of a functional human in vitro thyroid model which allows to further explore various aspects related to thyroid development and disease....

ea0063gp172 | Obesity (1) | ECE2019

Pituitary surgery as first-line therapy for microprolactinomas

Teulade Marie , Lasolle Helene , Vasiljevic Alexandre , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald

Introduction: Dopamine agonists (DA), reference treatment for microprolactinomas, rarely allow long term remission. The performance of endoscopic pituitary surgery should be examined as first-line treatment.Objective: To evaluate the remission rate of microprolactinoma operated by endoscopic transphenoidal approachMethods: We retrospectively studied the surgical results of the 35 microprolactinomas operated between 2010 to 2017 in ...

ea0056p870 | Pituitary - Clinical | ECE2018

Safety and efficacy of long-acting Pasireotide monotherapy in acromegalic patients treated with a combination of first-generation somatostatin analogs and cabergoline or pegvisomant

Lasolle Helene , Ferriere Amandine , Nunes Marie-Laure , Haissaguerre Magalie , Tabarin Antoine

Introduction: Combination therapy using pegvisomant and cabergoline with first-generation long-acting somatostatin analogs (1GSSA) is a common procedure in acromegalic patients that are not fully controlled by surgery and 1GSSA. Pasireotide-LAR is a new multireceptor-targeted somatostatin receptor ligand that has superior efficacy over octreotide LAR to control GH and IGF1 levels. Little data is available about the efficacy and safety of pasireotide monotherapy in patients tre...

ea0099p214 | Adrenal and Cardiovascular Endocrinology | ECE2024

Impact of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1

AGIUS Audrey , Juliette Abeillon , Amini-Adle Mona , Helene Lasolle , Borson-Chazot Francoise , Combemale Patrick , Kepenekian Lori

Background: In 2016, a prospective study conducted by our team found a prevalence of 7.7% of pheochromocytomas (Pheo) in patients with neurofibromatosis type 1 (NF1) if systematic screening including free metanephrines measurement (DMX) and abdominal imaging was performed. Half of Pheo were secreting, with 16% being symptomatic. This suggested the benefit of a systematic screening by abdominal imaging and DMX assay. The objective of this study was to evaluate the impact of sys...

ea0084op-01-06 | Oral Session 1: Topic Highlights | ETA2022

Modeling braf-induced thyroid cancer development and cell redifferentiation using pluripotent stem cell-derived organoids

Lasolle Helene , Gillotay Pierre , Ceolin Lucieli , Aganahi Benilda , Malta Letro Kizys Marina , Luiza Maia Ana , Costagliola Sabine , Romitti Mirian

Introduction: Due to their remarkable self-organizing structures and functional properties, organoid has become a powerful tool to model diseases ‘in a dish’. The use of organoids in cancer research emerged to better understand tumor behavior. Originally, adult stem cells (aSC)-derived organoids were derived from primary tumors while recent studies have reported the generation of cancer models arising from healthy cells by controlling oncogene expression. SC-derived ...

ea0056p784 | Pituitary - Basic | ECE2018

CGH array analysis of pituitary tumors revealed a highly-disrupted genome

Lasolle Helene , Elsensohn Mad-Helenie , Alix Eudeline , Bonnefille Clement , Michel Jessica , Bardel Claire , Roy Pascal , Sanlaville Damien , Raverot Gerald

Introduction: Genetic of pituitary tumors (PT) is incompletely understood. The aim of this study was to search for somatic copy number variations (CNV) in pituitary tumors and evaluate their prognostic impact on tumor recurrence.Methods: CGH array analysis (Agilent SurePrint G3 Human CGH+SNP Microarray 4×180 K) was performed on 196 fresh-frozen PT (67 gonadotroph, 31 corticotroph, 38 prolactinomas, 60 somatotroph). PT were classified according to th...

ea0041gp235 | Thyroid Cancer (1) | ECE2016

Thyroid nodules: a highly specific molecular and cytological combined predictor of malignancy

Lasolle Helene , Riche Benjamin , Decaussin Myriam , Dantony Emmanuelle , Cornu Catherine , Lifante Jean-Christophe , Capraru Oana-Maria , Rousset Bernard , Borson-Chazot Francoise , Roy Pascal

Thyroid nodules are very common and benign in most cases. Thus, malignancy detection avoiding overtreatment is a challenge. Nodule evaluation mainly supports on US and fine needle aspiration cytology (FNAC). The Bethesda classification (BC) for reporting thyroid cytopathology is now currently used for the interpretation of results but it does not enable classifying 30% of samples.The objective was to identify, by transcriptome analysis, a molecular signa...

ea0101op-13-05 | Oral Session 13: TED | ETA2024

Efficacy of teprotumumab on medical and surgical resistant don

Lucia Carretti Anna , Kielwasser Gauthier , Peiffert Mathilde , Bogaciu Teodora , Thia-Soui-Tchonga Kim , Jouanneau Emmanuel , Lasolle Helene , Castellnou Solene , Manet Romain , Abeillon-du Payrat Juliette

Dysthyroid Optic Neuropathy (DON) is a rare but sight threatening complication of Graves orbitopathy (GO), secondary to optic nerve compression or optic nerve stretching. A previous study from our group showed that medical and surgical treatment of DON according to EUGOGO guidelines resulted in a significant recovery in 70% of DON. However 30% had only partial or no recovery. Teprotumumab is an Insulin Growth Factor -1Receptor inhibitor (IGF-1R) showing impressive results in t...

ea0099p501 | Endocrine-Related Cancer | ECE2024

Clinical features and outcome in patients with functional head and neck paragangliomas: French national cohort and literature review

Pinigina Iuliia , Ceruse Philippe , Herman Philippe , Catherine Cardot , Haissaguerre Magalie , Cornu Erika , Amar Laurence , Batisse-Lignier Marie , Chardon Laurence , Barraud Sara , Feuvret Loic , Janier Marc , Helene Lasolle , Borson-Chazot Francoise , Juliette Abeillon

Objectives: Management of functional head and neck paragangliomas (HNPGLf) presents a substantial challenge due to their rarity, the lack of standardized treatment protocols, their complex neurovascular anatomical location, and the cardiovascular risks associated with catecholamine (CA) hypersecretion. This study aimed to describe the clinical characteristics of HNPGLf and their treatment outcomes.Methods: We retrospectively analyzed a cohort of HNPGLf p...

ea0101op-12-04 | Oral Session 12: Clinical thyroid cancer research | ETA2024

Pronosthyc: prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from a french network of referral centers

Sagnella Alfonso , Lasolle Helene , Godbert Yann , Do Cao Christine , Drui Delphine , Hescot Segolene , Laramas Mathieu , Sage Clemence , Wassermann Johanna , Roudaut Nathalie , Illouz Frederic , Borson-Chazot Francoise , Bachir Abdelouahab Macine , Hadoux Julien , Borget Isabelle , Buffet Camille , Lamartina Livia

Background: Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases show poor survival rates. However, patients’ outcome can be very heterogeneous, with cases spanning from microscopic slowly growing metastases to symptomatic, rapidly progressive disease. The aim of this study was to assess the overall survival (OS) of RAI-R DTC patients with distant metastases and to identify the prognostic factors associated with OS.<p class...